CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Continuous glucose monitoring (CGM) parameters may identify individuals at risk for progression to overt type 1 diabetes. We aimed to determine whether CGM metrics provide additional insights into progression to clinical stage 3 type 1 diabetes. RESEARCH DESIGN AND METHODS: One hundred five relatives of individuals in type 1 diabetes probands (median age 16.8 years; 89% non-Hispanic White; 43.8% female) from the TrialNet Pathway to Prevention study underwent 7-day CGM assessments and oral glucose tolerance tests (OGTTs) at 6-month intervals. The baseline data are reported here. Three groups were evaluated: individuals with 1) stage 2 type 1 diabetes (n = 42) with two or more diabetes-related autoantibodies and abnormal OGTT; 2) stage 1 type 1 diabetes (n = 53) with two or more diabetes-related autoantibodies and normal OGTT; and 3) negative test for all diabetes-related autoantibodies and normal OGTT (n = 10). RESULTS: Multiple CGM metrics were associated with progression to stage 3 type 1 diabetes. Specifically, spending ≥5% time with glucose levels ≥140 mg/dL (P = 0.01), ≥8% time with glucose levels ≥140 mg/dL (P = 0.02), ≥5% time with glucose levels ≥160 mg/dL (P = 0.0001), and ≥8% time with glucose levels ≥160 mg/dL (P = 0.02) were all associated with progression to stage 3 disease. Stage 2 participants and those who progressed to stage 3 also exhibited higher mean daytime glucose values; spent more time with glucose values over 120, 140, and 160 mg/dL; and had greater variability. CONCLUSIONS: CGM could aid in the identification of individuals, including those with a normal OGTT, who are likely to rapidly progress to stage 3 type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
An asymptotic equivalence of choice of model by cross validation and Akaike's criterion
Stone, M. (1977) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.2517-6161.1977.tb01603.x · Cited by 1,286
Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Self-citationContinuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Continuous glucose monitoring: A review of the technology and clinical use
Klonoff, D. C., Ahn, D., & Drincic, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.005 · Cited by 320
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer, J. P., Schatz, D. A., Bundy, B., Skyler, J. S., & Greenbaum, C. J. (2017) · JAMA · doi:10.1001/jama.2017.17070 · Cited by 214
Self-citationEarly prediction of autoimmune (type 1) diabetes.
Regnell, S. E., & Lernmark, Å. (2017) · Diabetologia · doi:10.1007/s00125-017-4308-1 · Cited by 195
Sosenko, J. M., Skyler, J. S., Palmer, J. P., Krischer, J. P., Yu, L., Mahon, J., Beam, C. A., Boulware, D. C., Rafkin, L., Schatz, D., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0425 · Cited by 123
Self-citation
Cited by
Baricitinib and β-cell function in patients with new-onset type 1 diabetes
Waibel, M., Wentworth, J. M., So, M., Couper, J. J., Cameron, F. J., MacIsaac, R. J., Atlas, G., Gorelik, A., Litwak, S., Sanz-Villanueva, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306691 · Cited by 194
Haller, M. J., Bell, K. J., Besser, R. E. J., Casteels, K., Couper, J. J., Craig, M. E., Elding Larsson, H., Jacobsen, L., Lange, K., Oron, T., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543035 · Cited by 151
“CGM is increasingly being used as a tool to predict progression to Stage 3 T1D [89 – 91], and to detect people who are asymptomatic in Stage 2 and Stage 3a [92].”
Self-citationPhillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E., Colhoun, H. M., Couper, J. J., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0042 · Cited by 79
Self-citation
Metadata
- Authors
- Wilson, D. M., Pietropaolo, S. L., Acevedo-Calado, M., Huang, S., Anyaiwe, D., Scheinker, D., Steck, A. K., Vasudevan, M. M., McKay, S. V., Sherr, J. L., Herold, K. C., Dunne, J. L., Greenbaum, C. J., Lord, S. M., Haller, M. J., Schatz, D. A., Atkinson, M. A., Nelson, P. W., Pietropaolo, M., & the Type 1 Diabetes TrialNet Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-02-02
- Volume
- 46
- Issue
- 3
- Pages
- 526-534
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4318960207
- Cited by
- 56
- References
- 12
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. https://app.cochat.ai/papers/10.2337/dc22-1297
- The paper
- Wilson, D. M., Pietropaolo, S. L., Acevedo-Calado, M., Huang, S., Anyaiwe, D., Scheinker, D., Steck, A. K., Vasudevan, M. M., McKay, S. V., Sherr, J. L., Herold, K. C., Dunne, J. L., Greenbaum, C. J., Lord, S. M., Haller, M. J., Schatz, D. A., Atkinson, M. A., Nelson, P. W., Pietropaolo, M., & the Type 1 Diabetes TrialNet Study Group. (2023). CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care. https://doi.org/10.2337/dc22-1297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.